Back to News
Market Impact: 0.35
Novo CEO says pills could capture 50% of weight-loss market by 2030
Source: reuters.com
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
Novo Nordisk's CEO said oral weight-loss pills could account for as much as 50% of the global obesity-drug market by 2030. The company is positioning for a market shift from weekly injectable treatments to pills, highlighting a significant long-term growth opportunity in obesity care.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVO0.45
More News
- Dozens of people sue GLP-1 drug companies over alleged vision loss
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- Novo CEO signals M&A opportunities to strengthen drug pipeline
- Novo Still Has Work to Do to Build Investor Confidence, CEO Says
- GLP-1 maker Novo Nordisk's big reveal leaves the City cold
- CNBC Daily Open: AI trade goes Meta after Muse launch